DERMAL SCIENCES UPDATE
Arch Launches
AC5® Advanced Wound System
Website

View Site

About Arch Therapeutics


Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2


1. AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2. AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

About

Learn more about Arch Therapeutics and
 its leadership team, poised to meet the challenges of applying innovative biotechnology to develop advanced interventional wound care products.

Learn More

Technology

The wound care market seeks products that work better, faster, & more reliably. See how Arch Therapeutics’ platform can address those needs.

Learn More

Pipeline

Find out more about Arch Therapeutics’ product candidates.

Learn More

Presentations

Find Arch Therapeutics’ recent presentations and more.

Learn More